BioPharma Resources

Drug Trial Radar · NCT07295873

Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide

A Single-Center, Open-Label, Single-Arm, Self-Controlled Phase I Clinical Study to Evaluate Drug-Drug Interactions of Hydronidone With Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide in Healthy Chinese Subjects

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Mar 15, 2026

Primary completion

May 29, 2026

Study completion May 29, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The proposed indication for Hydronidone Capsules is chronic hepatitis B-associated liver fibrosis, which in clinical practice typically requires concomitant use with antiviral agents for chronic hepatitis B. The commonly used chronic hepatitis B antiviral agents include Entecavir, Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF), and Tenofovir Amibufenamide (TMF). This study aims to evaluate the drug-drug interaction (DDI) of Hydronidone Capsules 90 mg with Entecavir, Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF), and Tenofovir Amibufenamide (TMF) respectively in healthy participants, to inform the preparation of post-marketing labeling and the development of concomitant dosing regimens in clinical practice.

Conditions

  • Chronic Hepatitis B Liver Fibrosis
  • DDI (Drug-Drug Interaction)

Interventions

  • EntecavirDrug

    0.5 mg, taken orally on an empty stomach, once a day

  • Tenofovir Disoproxil Fumarate(TDF)Drug

    300 mg, taken orally on an empty stomach, once a day

  • Tenofovir alafenamide(TAF)Drug

    25 mg, single oral dose, under fasting conditions

  • Tenofovir Amibufenamide(TMF)Drug

    25 mg, single oral dose, under fasting conditions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma hydronidone PK parameters of hydronidone capsules : steady-state peak concentration (Cmax,ss);Time frame: 23 days
  2. Plasma hydronidone PK parametersof hydronidone capsules : Area under the plasma concentration-time curve from time zero to 24 hours at steady state (AUC0-24h,ss)Time frame: 23 days
  3. Primary PK parameters of plasma of entecavir : AUC0-24h,ss.Time frame: 23 days
  4. Primary PK parameters of plasma of entecavir : Cmax,ss .Time frame: 23 days
  5. Primary PK parameters of plasma tenofovir alafenamide (TAF) : AUC0-24h,ss.Time frame: 23 days
  6. Primary PK parameters of plasma tenofovir alafenamide (TAF) : Cmax,ss .Time frame: 23 days
  7. Primary PK parameters of tenofovir disoproxil fumarate tablets (TDF): Cmax,ss .Time frame: 20 days
  8. Primary PK parameters of tenofovir disoproxil fumarate tablets (TDF): AUC0-24h,ss.Time frame: 20 days
  9. Primary PK parameters of plasma tenofovir amibufenamide (TMF) : Cmax,ss .Time frame: 23 days
  10. Primary PK parameters of plasma tenofovir amibufenamide (TMF) : AUC0-24h,ss.Time frame: 23 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Gaobo Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.